Ann: Anagrelide Project Update, page-49

That’s a pretty simplistic approach to valuing the company. It’s not expensive because it’s trading about the cap raise price. Your assessment should be made on a market cap basis.

Current market is $13m and SUD has ~$5m in cash.

So basically that means the market is assigning an $8m valuation (EV) to future Zolpimist cashflow, the TGA license, the entire Anagrelide project and its patents, Sumatriptan and its possible future cash flows, the cannabinoid projects, the 100’s of patents the company controls, the Oromist technology device (potential collaboration with Sanofi and others to reformulate pre-approved tablet form drugs) etc etc.

$8m in my opinion is ridiculously cheap. But that is just my opinion and I have been wrong many times, particularly on this one!